adenosine

FDA Drug Profile — adenosine, Adenosine, THE SKIN HOUSE Wrinkle SystemCream, SFERANGS COLLAGEN RECHARGINGCREAM, MULTI FUNCTION SLEEPING PACK

adenosine is listed in the FDA National Drug Code directory with 26 NDC codes, marketed under brand names including adenosine, Adenosine, THE SKIN HOUSE Wrinkle SystemCream. Available dosage forms: injection, injection, solution, cream, liquid, emulsion.

Drug details

Generic Name
adenosine
Brand Names
adenosine, Adenosine, THE SKIN HOUSE Wrinkle SystemCream, SFERANGS COLLAGEN RECHARGINGCREAM, MULTI FUNCTION SLEEPING PACK, YOMA AMPOULE PLUS COLLAGEN MASK PACK, THE SKIN HOUSE WRINKLE COLLAGEN AMPOULE, THE SKIN HOUSE Wrinkle System EyeCream, YOMA AMPOULE PLUS SNAIL MASK PACK, SFERANGS COLLAGEN RECHARGING, Tenue 24k gold ampoule, THE SKIN HOUSE Wrinkle System Essence, SFERANGS COLLAGEN SYNERGY AMPOULE, YOMA AMPOULE PLUS ALOE MASK PACK, YOMA AMPOULE PLUS GINSENG MASK PACK, SFERANGS COLLAGEN RECHARGING TONER, THE SKIN HOUSE Wrinkle Snail SystemCream, THE SKIN HOUSE Wrinkle CollagenEmulsion, THE SKIN HOUSE Wrinkle Collagen Toner, SFERANGS COLLAGEN RECHARGING SERUM
Application Number
ANDA078686
Sponsor
Mylan Institutional LLC
NDC Codes
26
Dosage Forms
INJECTION, INJECTION, SOLUTION, CREAM, LIQUID, EMULSION
Routes
INTRAVENOUS, TOPICAL
Active Ingredients
ADENOSINE

Indications and Usage

Indications and Usage Intravenous adenosine injection is indicated for the following. Conversion to sinus rhythm of paroxysmal supraventricular tachycardia (PSVT), including that associated with accessory bypass tracts (Wolff-Parkinson-White Syndrome). When clinically advisable, appropriate vagal maneuvers (e.g., Valsalva maneuver), should be attempted prior to adenosine injection administration. It is important to be sure the adenosine injection solution actually reaches the systemic circulation (see DOSAGE AND ADMINISTRATION ). Adenosine Injection does not convert atrial flutter, atrial fibrillation, or ventricular tachycardia to normal sinus rhythm. In the presence of atrial flutter or atrial fibrillation, a transient modest slowing of ventricular response may occur immediately following adenosine injection administration.

Warnings

Warnings Heart Block Adenosine Injection exerts its effect by decreasing conduction through the A-V node and may produce a short lasting first-, second- or third-degree heart block. Appropriate therapy should be instituted as needed. Patients who develop high-level block on one dose of adenosine injection should not be given additional doses. Because of the very short half-life of adenosine, these effects are generally self-limiting. Appropriate resuscitative measures should be available. Transient or prolonged episodes of asystole have been reported with fatal outcomes in some cases. Rarely, ventricular fibrillation has been reported following adenosine injection administration, including both resuscitated and fatal events. In most instances, these cases were associated with the concomitant use of digoxin and, less frequently with digoxin and verapamil. Although no causal relationship or drug-drug interaction has been established, adenosine injection should be used with caution in patients receiving digoxin or digoxin and verapamil in combination. Arrhythmias at Time of Conversion At the time of conversion to normal sinus rhythm, a variety of new rhythms may appear on the electrocardiogram. They generally last only a few seconds without intervention, and may take the form of premature ventricular contractions, atrial premature contractions, atrial fibrillation, sinus bradycardia, sinus tachycardia, skipped beats, and varying degrees of A-V nodal block. Such findings were seen in 55% of patients. Bronchoconstriction Adenosine Injection is a respiratory stimulant (probably through activation of carotid body chemoreceptors) and intravenous administration in man has been shown to increase minute ventilation (Ve) and reduce arterial PCO 2 causing respiratory alkalosis. Adenosine administered by inhalation has been reported to cause bronchoconstriction in asthmatic patients, presumably due to mast cell degranulation and histamine release. These effects have not been observed in normal subjects. Adenosine Injection has been administered to a limited number of patients with asthma and mild to moderate exacerbation of their symptoms has been reported. Respiratory compromise has occurred during adenosine infusion in patients with obstructive pulmonary disease. Adenosine Injection should be used with caution in patients with obstructive lung disease not associated with bronchoconstriction (e.g., emphysema, bronchitis, etc.) and should be avoided in patients with bronchoconstriction or bronchospasm (e.g., asthma). Adenosine Injection should be discontinued in any patient who develops severe respiratory difficulties.

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.